Clinical trial · Interventional
Technology-Enabled Activation of Skin Cancer Screening for Stem Cell Transplant Survivors and Their Primary Care Providers, TEACH Study
Technology-Enabled Activation of Skin Cancer Screening for Hematopoietic Cell Transplantation Survivors and Their Primary Care Providers (TEACH)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This trial studies the impact of a 12-month invention focused on early detection of skin cancer and timely follow up in patients who underwent stem cell transplant and their primary care providers. Some stem cell transplant survivors may develop complications related to the treatment they received. Many of these complications may not be known for years after the treatment and preventive measures can be taken to reduce the chances that a complication will occur and encourage early detection. This study focuses on one complication that stem cell transplant survivors are at high risk of developing - skin cancer. An early diagnosis of skin cancer is important since the cancer is usually smaller, requires less extensive treatments, and has better outcomes. Teaching skin self-examination and encouraging patients to alert doctors to skin changes may provide an important opportunity for early detection of skin cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Skin Carcinoma | Skin Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Computer-Assisted Intervention | Other | — | UNRESOLVED |
| Dermatoscope | Device | — | UNRESOLVED |
| Educational Intervention | Other | — | UNRESOLVED |
| Educational Intervention (Physician) | Other | — | UNRESOLVED |
| Questionnaire Administration | Other | — | UNRESOLVED |
| Text Message | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Group I (PAE)
- description
- Participants receive a study packet on skin cancer. Participants also receive text messages once every 3 weeks for 9 months.
- interventionNames
- Other: Educational Intervention
- Other: Questionnaire Administration
- Other: Text Message
- type
- EXPERIMENTAL
- label
- Group II (PAE, physician)
- description
- Participants receive a study packet on skin cancer. Participants also receive text messages once every 3 weeks for 9 months. Participants' physician receives a letter that describes the educational intervention and encourages them to do a skin examination at next patient visit.
- interventionNames
- Other: Educational Intervention
- Other: Educational Intervention (Physician)
- Other: Questionnaire Administration
- Other: Text Message
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Have undergone autologous or allogeneic hematopoietic stem cell transplantation (HCT) at City of Hope (COH) * Are 2 years (yrs) to 5 yrs (+/- 3 months \[m\]) after HCT * Have seen a primary care provider (PCP) in the previous 12 m (expected \> 95% of all eligible) or planning to do so in next 12 m * Have a mobile phone with the ability to receive text messages * Can fluently read and write in English or Spanish * Can understand and sign the study-specific Informed Consent Form (ICF) Exclusion Criteria: * Patients who have evidence of active hematologic malignancy or acute illness that would limit study participation
References
Publications (2)
- DERIVEDArmenian SH, Du X, Bosworth A, Rodarte S, Balasian E, Boyapalli S, Herrera C, Echevarria M, Lindenfeld L, Al Malki M, Nakamura R, Modi B, Oeffinger KC, Emmons KM, Marghoob AA, Forman SJ, Wong FL, Geller AC. Technology-Enabled Patient and Physician Activation to Enhance Skin Cancer Screening After HCT: A Randomized Controlled Trial. J Natl Compr Canc Netw. 2026 Aug 6:1-8. doi: 10.6004/jnccn.2026.7030. Online ahead of print. PMID 42562001
- DERIVEDArmenian SH, Lindenfeld L, Iukuridze A, Echevarria M, Bebel S, Coleman C, Nakamura R, Abdullah F, Modi B, Oeffinger KC, Emmons KM, Marghoob AA, Geller AC. Technology-enabled activation of skin cancer screening for hematopoietic cell transplantation survivors and their primary care providers (TEACH). BMC Cancer. 2020 Aug 3;20(1):721. doi: 10.1186/s12885-020-07232-2. PMID 32746799